Trump Executive Order Stalls Medicare Drug Price Negotiations

The order, titled "Lowering Drug Prices by Once Again Putting Americans First," seeks to add four years to the current timeline for price negotiations. Under the Inflation Reduction Act, small-molecule drugs—which account for 90% of circulating medications—are currently exempt for nine years following FDA approval. By pushing this deadline further, the administration aligns with industry arguments that the current law creates a "pill penalty" for traditional medications compared to biologics.

Critics argue the move effectively dismantles a key mechanism designed to curb drug costs. Steve Knievel, a policy advocate at Public Citizen, warned that the delay would result in higher prices for taxpayers and seniors rather than lowering them. Advocacy group Protect Our Care described the directive as a capitulation to corporate interests, noting that the language mirrors campaigns previously pushed by industry-backed shell organizations like the American Prosperity Alliance.

Republican lawmakers in the House and Senate have already signaled support for this shift, with several members having previously introduced legislation to achieve similar delays. Merith Basey, executive director of Patients for Affordable Drugs, characterized the push as a systemic effort to rig pricing structures in favor of manufacturers. The administration's move sets the stage for a legislative battle over the future of Medicare’s bargaining power, which has only recently begun to yield results.